open access
Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors
open access
Abstract
Methods: Over the course of three years (2004-2006) 394 consecutive patients presenting with STEMI were included in this single centre experience. There were 95 patients (24%) with, and 299 patients (76%) without, diabetes. A GP IIb/IIIa inhibitor was administered to all patients without contraindications (316 patients, 80%).
Results: Patients with diabetes were significantly older, more often suffered from hypertension and had a higher incidence of obesity. The rate of administration of GP IIb/IIIa inhibitors was similar in both groups (74% vs. 82%, p = 0.14). The in-hospital incidence of major adverse cardiac events (MACE, defined as death, re-myocardial infarction, target lesion revascularisation and coronary artery bypass graft) was similar in both patient groups (18 [19%] diabetics vs. 51 [17%] non-diabetics, p = 0.65). Hypertension, age and obesity were identified as predictors for MACE, whereas diabetes was not predictive.
Conclusions: In this single centre experience, in diabetic and non-diabetic patients presenting with STEMI, combination therapy with primary PCI and GP IIb/IIIa inhibitors might have contributed to a similar clinical outcome.
Abstract
Methods: Over the course of three years (2004-2006) 394 consecutive patients presenting with STEMI were included in this single centre experience. There were 95 patients (24%) with, and 299 patients (76%) without, diabetes. A GP IIb/IIIa inhibitor was administered to all patients without contraindications (316 patients, 80%).
Results: Patients with diabetes were significantly older, more often suffered from hypertension and had a higher incidence of obesity. The rate of administration of GP IIb/IIIa inhibitors was similar in both groups (74% vs. 82%, p = 0.14). The in-hospital incidence of major adverse cardiac events (MACE, defined as death, re-myocardial infarction, target lesion revascularisation and coronary artery bypass graft) was similar in both patient groups (18 [19%] diabetics vs. 51 [17%] non-diabetics, p = 0.65). Hypertension, age and obesity were identified as predictors for MACE, whereas diabetes was not predictive.
Conclusions: In this single centre experience, in diabetic and non-diabetic patients presenting with STEMI, combination therapy with primary PCI and GP IIb/IIIa inhibitors might have contributed to a similar clinical outcome.
Keywords
myocardial infarction; ST-elevation myocardial infarction; diabetes mellitus; GP IIb/IIIa; percutaneous coronary intervention
About this articleTitle
Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors
Journal
Issue
Pages
234-240
Published online
2009-03-10
Page views
942
Article views/downloads
1558
DOI
10.5603/cj.21500
Bibliographic record
Cardiol J 2009;16(3):234-240.
Keywords
myocardial infarction
ST-elevation myocardial infarction
diabetes mellitus
GP IIb/IIIa
percutaneous coronary intervention
Authors
Stefan Kralev
Barbara Krause
Theano Papavassiliu
Siegfried Lang
Dariusch Haghi
Thorsten Kälsch
Carl-Erik Dempfle
Martin Borggrefe
Tim Süselbeck
